Primary central nervous system lymphoma (PCNSL) represents an aggressive subset of lymphoma exclusively affecting the CNS (brain parenchyma, spinal cord, eyes, cranial nerves and / or meninges). r Diffuse large B-cell lymphoma (DLBCL) comprises the majority (90%) of PCNSL. r Landmark prospective randomised clinical trials have led to the. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial Nursing. Forthcoming section for nursing specific resources on caring for patients with lymphomas. Ferreri / IELSG Protocol (High-dose Cytarabine plus High-dose Methotrexate) for Primary CNS Lymphoma Page 1 of 3 Reason for Update: Network Protocol Development Approved by Consultant: Paul Fields Cytarabine reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI). Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma Note 1: Regimens specifically intended for HIV-related Burkitt lymphoma can be found on the HIV-associated lymphoma page. Note 2: The regimens on this page are primarily intended for the sporadic form of Burkitt lymphoma and some other high-grade B-cell lymphomas. The supportive therapies (e.g. antiemetics, premedications, etc.), infusion times, diluents, volumes and routes of administration, if included, are listed as defaults. High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study BC Cancer Protocol Summary for Treatment of Lymphoma with Dose-Adjusted Etoposide, DOXOrubicin, vinCRIStine, Cyclophosphamide, predniSONE and riTUXimab with Intrathecal Methotrexate.